D-galactose study for PGM1-CDG
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study tests a sugar called D-galactose to see if it is safe and works well for people with PGM1-CDG, a rare genetic condition that affects how the body uses sugar. If you are already taking D-galactose, this trial will check if it helps your symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with PGM1-CDG through genetic testing.
- You are currently taking a stable dose of D-galactose.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
- You do not have certain other conditions like aldolase B deficiency, galactosemia, or severe anemia.
- You have not had severe reactions to galactose in the past, such as severe diarrhea or vomiting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a sugar called D-galactose given as a supplement to help with symptoms of SLC35A2-CDG, a rare genetic condition that can cause seizures and digestive problems. The goal is to see if taking this sugar improves those symptoms.
This study is for people who already completed a previous trial of GLM101 for PMM2-CDG. It offers continued access to the treatment while doctors monitor safety and effects.
This trial tests a new gene therapy (VGM-R02b) for children with Glutaric Acidemia Type 1 (GA-1) whose symptoms are not well controlled by standard treatment. The goal is to see if the therapy is safe and can help improve neurological symptoms.
This trial tests giving a gene therapy directly to a baby before birth to treat GM1 gangliosidosis, a rare genetic condition that damages the brain and body. The treatment aims to replace the missing enzyme to help the baby develop healthier.
This early-stage study tests an IV gene therapy that delivers a working copy of an enzyme gene to help the body make beta-galactosidase in GM1 gangliosidosis. It may help slow or improve disease symptoms and looks closely at safety and how well the treatment works.
This trial is for people who have a confirmed genetic condition related to how the body builds certain sugar-like structures (CDG) or NGLY1 deficiency. It aims to better understand these conditions through clinical and basic science research, which may help improve future care.
Hear when a new PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.